Status:
COMPLETED
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
United States Department of Defense
Genentech, Inc.
Conditions:
Breast Cancer Metastases
HER2 Positive Breast
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these ...
Eligibility Criteria
Inclusion
- Women age \> 18
- Biopsy proven HER2 negative primary breast cancer and biopsy proven metastatic disease.
- 5 or more foci of demonstrable metastases on recent imaging modalities (CT, MR, FDG PET/CT)
- ECOG performance score of 0-2
Exclusion
- Life expectancy \< 3months
- Pregnancy or lactation
- Patients who cannot undergo PET/CT scanning because of weight limits
- CNS only disease on recent imaging
Key Trial Info
Start Date :
November 6 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT02286843
Start Date
November 6 2014
End Date
June 30 2020
Last Update
June 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065